Trials / Completed
CompletedNCT00751621
Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)
A Multicenter Extension Study of the Efficacy, Tolerability, and Safety of Immune Globulin Subcutaneous (Human) IgPro20 in Subjects With Primary Immunodeficiency (IgPro20 EU Extension Study)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- CSL Behring · Industry
- Sex
- All
- Age
- 2 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is a continuation of the study ZLB06\_001CR with the objective of assessing efficacy, tolerability, safety of IgPro, as well as long-term health-related quality of life in patients with PID.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IgPro20 |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2011-12-01
- Completion
- 2011-12-01
- First posted
- 2008-09-12
- Last updated
- 2014-04-02
- Results posted
- 2013-01-25
Locations
13 sites across 8 countries: France, Germany, Poland, Romania, Spain, Sweden, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00751621. Inclusion in this directory is not an endorsement.